Theralase(R) Expands Clinical Team
Theralase(R) Expands Clinical Team
TORONTO, ON / ACCESSWIRE / May 2, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds ("PDCs") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has expanded its clinical team with the hiring of two Clinical Research Associates ("CRAs").
安大略省多倫多/ACCESSWIRE/2024年5月2日/Theralase Technologies Inc.(“Theralase” 或 “公司”)(TSXV: TLT)(OTCQB: TLTFF)是一家臨床階段製藥公司,致力於研發用於安全有效地消滅各種癌症、細菌和病毒的光和/或輻射活化光動力化合物(“PDC”),欣然宣佈,它已經僱用了兩名臨床研究助理(“CRA”),擴大了其臨床團隊。
Effective March 4th and May 1st, 2024, respectively, Bhavya Bajantri M.Sc., CCRP and Sonia Keshwani B.Sc., CCRP have joined Theralase in the capacity of CRAs.
3 月 4 日生效第四 還有 5 月 1 日st,2024年,Bhavya Bajantri M.Sc.、CCRP和Sonia Keshwani理學士、CCRP分別以CRA的身份加入Theralase。
The roles of the CRAs will be to work with the clinical study sites to successfully complete the Phase II registration bladder cancer clinical study ("Study II") by:
CRA的作用將是與臨床研究場所合作,通過以下方式成功完成II期註冊膀胱癌臨床研究(“第二項研究”):
- Launching new clinical study sites in Canada and the United States.
- Enrolling all patients into the clinical study in 2024.
- Reviewing and analyzing the existing clinical data to ensure accuracy.
- Securing review ethics board approval and patient consent to obtain patient clinical data up to 3 years from date of primary Study Procedure.
- Providing training and support on central pathology analysis of urine cytology and bladder biopsy pathology samples.
- Supporting Break Through Designation approval from the FDA in 3Q2024.
- 在加拿大和美國推出新的臨床研究地點。
- 2024 年招收所有患者參加臨床研究。
- 審查和分析現有臨床數據以確保準確性。
- 獲得審查倫理委員會的批准和患者的同意,以便在初步研究程序之日起3年內獲得患者臨床數據。
- 就尿液細胞學和膀胱活檢病理樣本的中心病理學分析提供培訓和支持。
- 支持 FDA 在 3Q2024 中獲得的突破性指定批准。
Roger DuMoulin-White, President and Chief Executive Officer, Theralase stated, "The Company looks forward to working with Bhavya and Sonia in their new roles and their participation in the successful and timely completion of Study II. The ultimate goal of our ongoing Phase II clinical study is to commercialize RuvidarTM in Canada, the United States and internationally to provide a safe and effective treatment for as many patients, as possible, who are afflicted with this deadly disease."
Theralase總裁兼首席執行官羅傑·杜穆林-懷特表示,”公司期待與Bhavya和Sonia在新職位上合作,並參與成功及時完成第二項研究。我們正在進行的二期臨床研究的最終目標是將Ruvidar商業化TM 在加拿大、美國和國際上,爲儘可能多的患有這種致命疾病的患者提供安全有效的治療。”
About Theralase Technologies Inc.:
關於 Theralase 科技公司:
Theralase is a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Theralase是一家臨床階段的製藥公司,致力於研究和開發光活化合物、其相關藥物配方和激活它們的光系統,其主要目標是療效,次要目標是銷燬各種癌症、細菌和病毒的安全性。
Additional information is available at and
更多信息可在和
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
Forward Looking Statements:
前瞻性陳述:
This news release contains "forward-looking statements" within the meaning of applicable Canadian securities laws. Such statements include; but are not limited to statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Forward looking statements may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of Company's management for future research, development and commercialization of the Company's Photo Dynamic Compounds and their drug formulations, preclinical research, clinical studies and regulatory approvals.
本新聞稿包含適用的加拿大證券法所指的 “前瞻性陳述”。此類聲明包括但不限於有關公司光動力化合物及其藥物配方的擬議開發計劃的聲明。前瞻性陳述可以通過使用 “可能、“應該”、“將”、“預期”、“相信”、“計劃”、“期望”、“估計”、“潛力” 等詞語來識別;包括與公司管理層當前對公司光動態化合物及其藥物配方、臨床前研究、臨床研究和監管批准的未來研究、開發和商業化預期相關的陳述。
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its drug formulations, the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or may not be available at all, the risk that the Company's drug formulations may not be effective against the diseases tested in its clinical studies, the risk that the Company's fails to comply with the term of license agreements with third parties and as a result loses the right to use key intellectual property in its business, the Company's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
這些陳述涉及重大風險、不確定性和假設;包括公司爲成功及時完成NMIBC二期臨床研究和實施其發展計劃提供資金和獲得監管批准的能力。其他風險包括:公司成功將其藥物製劑商業化的能力,可能無法按照對公司有利的商業條件或根本無法獲得足夠的資金來爲公司運營提供資金的風險,公司的藥物配方可能對臨床研究中測試的疾病無效的風險,公司未能遵守與第三方簽訂的許可協議條款的風險,以及作爲第三方的許可協議條款的風險結果失去了使用關鍵知識產權的權利在其業務中,公司保護其知識產權的能力、提交、接受和批准監管文件的時機和成功程度。這些決定實際業績的因素中有許多超出了公司的控制或預測能力。
Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate as such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements.
讀者不應過度依賴這些前瞻性陳述,這些陳述並不能保證未來的表現。無法保證前瞻性陳述會被證明是準確的,因爲此類前瞻性陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致實際業績或未來事件與前瞻性陳述存在重大差異。
Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
儘管新聞稿中包含的前瞻性陳述基於管理層目前認爲的合理假設,但公司無法向潛在投資者保證實際業績、業績或成就將與這些前瞻性陳述一致。
All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements.
所有前瞻性陳述均自本文發佈之日起作出,可能會發生變化。除非法律要求,否則公司沒有義務更新此類聲明。
For More Information:
欲了解更多信息:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
1.866..LASE (843-5273)
416.699.LASE (5273)
Kristina Hachey, CPA
Chief Financial Officer
khachey@theralase.com
克里斯蒂娜·哈奇,註冊會計師
首席財務官
khachey@theralase.com
SOURCE: Theralase Technologies Inc.
資料來源:Theralase Technologies